UNSPSC 51202700: Immunosupressant immunoglobulins

This classification denotes multi-subunit proteins central to human immunity, produced by b lymphocytes from the immunoglobulin genes, substances called immunoglobulins, that reduce a human host's humoral and/or cell-mediated defense mechanisms against deviant native cells, foreign organisms, or foreign substances (the human immune response and system thereof), thus the term IMMUNOSUPRESSANT IMMUNOGLOBULINS.

UNSPSC 51202700 Immunosuppressant immunoglobulins is a Class code that encompasses pharmaceutical products and medical supplies procured by state and local health agencies, but recent state and local opportunities tagged under this code show little alignment with its nominal scope — the code instead appears in solicitations for emergency medical supplies, naloxone, direct-to-manufacturer prescription programs, and generic pharmaceuticals. State and local issuing bodies soliciting under or near this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), municipal fire departments (Tampa Fire Department), and multistate cooperative purchasing alliances (MMCAP). The work being solicited ranges from tactical emergency response supplies and overdose reversal products to strategic pharmaceutical sourcing and bulk generic medication procurement, reflecting the heterogeneous use of pharmaceutical UNSPSC codes across jurisdictions.

Recent activity centers in Florida, Texas, and Minnesota. Seminole County released an IFB on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023 response deadline, with an estimated two-year term and one-year renewal option. The City of Tampa issued an ITB on March 25, 2026 for medical and first aid supplies (169 line items including respiratory equipment, cardiac monitoring electrodes, and consumables) designated as a sheltered-market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount capped at $10,000 and an estimated contract value of $700,000. The Texas HHS Commission posted an RFI on April 3, 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, with no award values or timelines specified at this exploratory stage. MMCAP (Minnesota Multistate Cooperative Purchasing Alliance), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities, requiring compliance with cGMP and DSCSA and pricing flexibility across multiple formats, with contract effectiveness set for July 1, 2026.